ClinicalTrials.gg
RecruitingNCT07871110Updated Oct 13, 2026

Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)

A Phase 2 interventional study of tinengotinib 10 mg QD plus darolutamide and tinengotinib 10 mg QD (2-week on / 1-week off) plus darolutamide in Prostate Cancer (CRPC), sponsored by TransThera Sciences (Nanjing), Inc.. Recruiting at 16 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by TransThera Sciences (Nanjing), Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 541 studies in Prostatic Neoplasms with a site in China — 281 open to participants now, 342 under way, 51 of them phase 3. Prostatic Neoplasms · China.

Planned enrollment
157th of 435
182 · median 100
Started
2026
with 82 others
Phase 2
84 of 541
51 open now
Primary completion
2028-12
later than 290 of 341 live
Registered
533rd of 541
by date

Among the 541 studies in Prostatic Neoplasms with a site in China, this one is the 157th largest by planned enrollment of the 435 interventional ones that give a count, is one of 83 that started in 2026, is one of 84 in phase 2, reaches primary completion later than 290 of the 341 other live ones, and was the 533rd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

281 of the 541 studies in Prostatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

275 more — sign in →

All 281 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 541 studies in Prostatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if tinengotinib combined with darolutamide or enzalutamide works to treat participants with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior androgen receptor pathway inhibitors (ARPIs). It will also learn about the safety of the combination therapy. The main questions it aims to answer are:

  1. If participants with mCRPC can benefit from the combination therapy of tinengotinib plus one ARPI?
  2. What medical problems do participants have when taking the combination therapy? Participants will take tinengotinib with darolutamide or enzalutamide to find the optimal dose and regimen of tinengotinib for the combination therapy in stage A. In stage B, participants will take preferred combination regimen of tinengotinib plus darolutamide/enzalutamide identified in stage A. In stage C, researchers will compare selected combination therapy versus standard treatment and/or monotherapy to see if the combination therapy works better.
03

Conditions studied

  • Prostate Cancer (CRPC)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male aged >= 18 years at the time of signing the form (ICF).
  2. or cytologically confirmed prostate adenocarcinoma; neuroendocrine differentiation after prior treatment is permitted (patients with de novo neuroendocrine prostate cancer at initial diagnosis are excluded).
  3. Baseline imaging confirming lesions in bone (>=2 bone lesions) or soft tissue; lesions identified only by PET imaging are not acceptable.
  4. Receipt of continuous medical castration for >=90 days or prior surgical castration, with serum testosterone \< 50 ng/dL (1.73 nmol/L) within 28 days prior to the first dose. Participants receiving medical castration with a luteinizing hormone-releasing hormone (LHRH) analogue must continue treatment throughout the study.
  5. Documented disease progression (per v1.1 and/or PCWG3) after >1 month of prior novel endocrine therapy (including abiraterone and AR inhibitors).

    Cohort B: Prior exposure to only one type of novel endocrine therapy.

  6. Disease failure after \<=1 administered during the castration-resistant phase (chemotherapy duration \<=1 month and ADC agents are not counted as systemic chemotherapy).
  7. performance status \<= 1.
  8. Adequate organ and bone marrow function (no hematopoietic growth factors, blood transfusion or related blood products within 14 days before the first dose).
  9. Must agree not to donate sperm or cryopreserve sperm for future assisted reproduction during study treatment and for 3 months after the last dose of study treatment. If the participant is spermatogenic and his female partner is of , highly effective must be used.
  10. Able to provide informed consent and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with tyrosine kinase inhibitors (TKIs).
  2. Prior treatment with darolutamide or enzalutamide (except for treatment duration \<= 1 month).
  3. Uncontrolled hypertension (systolic blood pressure >=150 mmHg or diastolic blood pressure >=100 mmHg; repeat measurement is permitted after an interval of >=10 minutes if abnormal), or a medical history of hypertensive crisis/hypertensive encephalopathy. Uncontrolled is defined as failure to achieve blood pressure control despite antihypertensive therapy with stable type/dose for at least 1 week.
  4. Concurrent central nervous system (CNS) with radiological or symptomatic progression within 28 days prior to study treatment initiation.
  5. Concurrent other requiring active treatment. Malignancies not requiring treatment within 5 years and cured localized tumors such as basal cell carcinoma of the skin, papillary thyroid carcinoma, etc., are excluded from this criterion.
  6. Prior administration of other anti-tumor therapies within \<=5 half-lives or 14 days (whichever is shorter) before initiation of study treatment, or failure to recover from adverse events of prior therapy (except for adverse events \<= Grade 1 or \<= Grade 2 adverse events judged by the investigator not to pose a safety risk). Sex hormone therapies other than LHRH agents must be discontinued >=7 days before study drug administration.
  7. Receipt of extensive radiotherapy within 4 weeks prior to study treatment initiation, or palliative local radiotherapy within 2 weeks, or failure to recover from adverse events of prior therapy. (If the investigator considers that early initiation of study drug is in the participant's best interest based on benefit-risk assessment, study drug treatment may be started during the upon sponsor approval.)
  8. Major surgery within 4 weeks prior to study treatment initiation, or failure to recover from surgical adverse events (except for adverse events \<= Grade 1 or \<= Grade 2 adverse events judged by the investigator not to pose a safety risk). 9. History of severe cardiovascular or cerebrovascular diseases.

10. Severe gastrointestinal disease or gastrointestinal dysfunction that may alter the absorption, metabolism or excretion of the study drug; eligibility will be determined by investigator assessment (including but not limited to total gastrectomy, short bowel syndrome, etc.).

11. Bleeding disorders, thrombotic disorders, or therapeutic anticoagulation requiring monitoring, such as warfarin or any other coumarin derivative anticoagulants.

12. Use of strong inhibitors and other agents that may affect the metabolism of the study drug within \<=2 weeks or 5 half-lives (whichever is shorter) prior to study treatment initiation. Other agents that may affect the concomitant medications are as follows: (1) Participants receiving enzalutamide combination therapy: use of strong CYP2C8 inhibitors; (2) Participants receiving darolutamide combination therapy: use of rosuvastatin, strong P-gp inhibitors and inducers.

13. Positive (HIV) test. 14. Active infection (abnormal HBV serology other than positive hepatitis B surface antibody; HBV DNA copy number testing is required to confirm activity) and/or infection (HCV RNA copy number testing is required to confirm activity if HCV antibody is positive).

15. Inability to swallow or tolerate oral medication. 16. Other conditions judged by the investigator to make the participant unsuitable for study participation.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
182 participants (estimated)

Study arms

  • Experimental
    Stage A (tinengotinib plus darolutamide)

    Drug: tinengotinib 10 mg QD plus darolutamide

  • Experimental
    Stage A (tinengotinib (2-week on / 1-week off) plus darolutamide)

    Drug: tinengotinib 10 mg QD (2-week on / 1-week off) plus darolutamide

  • Experimental
    Stage A (tinengotinib plus enzalutamide)

    Drug: tinengotinib 10 mg QD plus enzalutamide

  • Experimental
    Stage B (combination therapy)

    optimized combination regimen

    Drug: preferred combination regimen of tinengotinib plus one ARPI

  • Experimental
    Stage C (combination therapy)

    selected combination regimen

    Drug: selected combination regimen of tinengotinib plus one ARPI

  • Active comparator
    Stage C (ARPI monotherapy therapy)

    Drug: Darolutamide 600 mg twice daily

  • Active comparator
    Stage C (physician choice)

    Drug: Enzalutamide 160mg daily (oral)

Interventions

  • Drugtinengotinib 10 mg QD plus darolutamide

    Drug page: Tinengotinib

    Participants will receive tinengotinib 10 mg once daily with darolutamide in 21-day cycles per protocol defined schedule.

  • Drugtinengotinib 10 mg QD (2-week on / 1-week off) plus darolutamide

    Drug page: Tinengotinib

    Participants will receive tinengotinib 10 mg once daily (2-week on / 1-week off) with darolutamide in 21-day cycles per protocol defined schedule.

  • Drugtinengotinib 10 mg QD plus enzalutamide

    Drug page: Tinengotinib

    Participants will receive tinengotinib 10 mg once daily with enzalutamide in 21-day cycles per protocol defined schedule.

  • Drugpreferred combination regimen of tinengotinib plus one ARPI

    Participants will receive preferred combination regimen of tinengotinib at optimized dose plus one ARPI in 21-day cycles per protocol defined schedule.

  • Drugselected combination regimen of tinengotinib plus one ARPI

    Participants will receive selected combination regimen of tinengotinib at optimized dose plus one ARPI in 21-day cycles per protocol defined schedule.

  • Participants will receive darolutamide 600 mg twice daily in 21-day cycles per protocol defined schedule.

  • Participants will receive enzalutamide 160mg daily (oral) in 21-day cycles per protocol defined schedule.

06

What researchers measure

Primary outcomes

  1. Stage A: safety evaluation parameters

    Including dose-limiting toxicities (DLTs), and incidence, duration, and severity of other adverse events (AEs)

    Time frame: From signing of the informed consent until 28 days after the last dose or the end of the study (whichever occurs first), an average of 1 year.

  2. Stage B: 6-month PFS rate (6mo-PFS)

    The proportion of patients who remain alive without disease progression at 6 months after study treatment initiation. Tumor assessments are based on RECIST v1.1 and/or PCWG3.

    Time frame: From first study drug administration to the end of treatment, an average of 1 year.

  3. Stage C: Radiographic progression-free survival (rPFS)

    The time from randomization or treatment initiation to the first documented radiographic disease progression or death from any cause, whichever occurs first. Tumor assessments are based on RECIST v1.1 and/or PCWG3.

    Time frame: From first study drug administration to the end of treatment, an average of 1 year.

07

Study locations

1 of 16 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Dec 2028, 27 months after the start.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's planned 27 months is below that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2026
First posted
Oct 13, 2026
StartActual
Sep 18, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Jun 30, 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07871110
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Responsible party
Sponsor
First posted
Oct 13, 2026
Start date
Sep 18, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Caixia Sun, MD
Contact
sun_caixia@transtherabio.com
025-58216298

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tinengotinib

Start the discussion